Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
Arq Bras Cardiol. 2018 Jul;111(1):104-108.
doi: 10.5935/abc.20180133.
[Article in
English,
Portuguese]
Affiliations
- 1 Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS - Brazil.
- 2 Faculdade de Medicina - Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil.
- 3 Serviço de Cardiologia - Hospital de Clínicas de Porto Alegre, Porto Alegre - Brazil.
- 4 Instituto de Cardiologia / Fundação Universitária de Cardiologia, Porto Alegre, RS - Brazil.
- 5 Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS - Brazil.
- 6 Hospital Nossa Senhora da Conceição, Porto Alegre, RS - Brazil.
No abstract available
MeSH terms
-
Antibodies, Monoclonal / economics
-
Antibodies, Monoclonal / therapeutic use*
-
Cardiovascular Diseases / economics
-
Cardiovascular Diseases / enzymology
-
Cardiovascular Diseases / prevention & control*
-
Cholesterol, LDL / blood
-
Cost-Benefit Analysis
-
Humans
-
PCSK9 Inhibitors*
-
Proprotein Convertase 9 / economics
-
Risk Factors
Substances
-
Antibodies, Monoclonal
-
Cholesterol, LDL
-
PCSK9 Inhibitors
-
PCSK9 protein, human
-
Proprotein Convertase 9